Study Overview
Tarnopolsky (2000) published a seminal review examining the potential therapeutic applications of creatine monohydrate in neuromuscular diseases.
The review synthesised evidence from clinical trials and mechanistic studies exploring creatine’s effects in conditions including muscular dystrophy (Duchenne, Becker, and myotonic), mitochondrial myopathies, and other neuromuscular disorders.
This work expanded the understanding of creatine beyond sports performance into clinical medicine (Roschel et al., 2021) .
Key Findings
- Improved strength in muscular dystrophy: Clinical trials demonstrated that creatine supplementation produced modest but significant improvements in muscle strength and functional measures in patients with various forms of muscular dystrophy
- Benefits in mitochondrial myopathies: Patients with mitochondrial disorders — conditions directly affecting cellular energy production — showed improvements in exercise tolerance and some measures of strength with creatine supplementation
- Mechanism through energy buffering: The therapeutic mechanism relates to creatine’s fundamental role in cellular energy metabolism. In diseases where energy production is compromised, replenishing phosphocreatine stores helps buffer against energy deficits
- Neuroprotective potential: The review also noted creatine’s potential neuroprotective effects, suggesting benefits may extend beyond muscle to neurons affected by neuromuscular diseases
- Well-tolerated: Creatine was well-tolerated in patient populations with no significant adverse effects reported
Practical Implications
Tarnopolsky’s work was significant in shifting the scientific conversation about creatine from purely a sports supplement to a potential therapeutic agent.
This has implications for understanding creatine’s broader biological role — if it can help diseased muscles function better, it underscores the importance of the phosphocreatine system for normal muscle function.
For the general Malaysian population, this research reinforces the fundamental importance of the phosphocreatine energy system and supports the rationale for creatine supplementation in aging adults, whose cellular energy metabolism naturally declines.
For Malaysian families affected by neuromuscular diseases, this research provides a basis for discussing creatine supplementation with their medical team as a potential supportive therapy.
It is important to emphasise that creatine should complement, not replace, standard medical treatment (Wallimann et al., 2011) .
Study Limitations
- Many of the clinical trials reviewed had small sample sizes
- Disease heterogeneity makes it difficult to generalise findings across all neuromuscular conditions
- Long-term effects of creatine supplementation in neuromuscular disease patients have not been extensively studied
- Optimal dosing protocols for patient populations may differ from those established in healthy individuals
- The review included mostly short-term studies — the sustainability of benefits over years is unclear
Mechanism of Action
Understanding the biochemistry behind creatine's effects provides context for the practical recommendations in this guide. Creatine functions primarily through the ATP-phosphocreatine (ATP-PCr) system:
- Storage: Approximately 95% of the body's creatine is stored in skeletal muscle, with the remaining 5% in the brain, kidneys, and liver
- Conversion: The enzyme creatine kinase attaches a high-energy phosphate group to free creatine, creating phosphocreatine (PCr)
- Energy release: During high-intensity activity, PCr rapidly donates its phosphate group to ADP, regenerating ATP within milliseconds
- Resynthesis: During rest periods, the process reverses — ATP donates a phosphate back to creatine, replenishing PCr stores
This cycle operates continuously in all metabolically active tissues. Supplementation increases the total creatine pool by 20-40%, expanding the energy buffer available for intense physical and cognitive work.
Where This Fits in the Evidence
Tarnopolsky’s review is best read as hypothesis-generating rather than definitive. It gathers small clinical trials across very different neuromuscular diseases, where sample sizes are limited, effects are modest, and disease heterogeneity makes pooling difficult. The strongest creatine evidence still comes from healthy and ageing populations; the value of this work was in opening the clinical question of whether supporting the phosphocreatine system can help diseased muscle. For patients and families, that makes it a basis for conversation with a neurologist or care team — not a treatment recommendation on its own. The broader evidence base is collected in our research library.
Sources & References
This page summarises Tarnopolsky M. Potential benefits of creatine monohydrate supplementation in the elderly. Current Opinion in Clinical Nutrition and Metabolic Care.
2000;3(6):497-502. Also reviewed: Tarnopolsky MA, Beal MF.
Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Annals of Neurology.
2001;49(5):561-574.